Impact of fixed pulmonary hypertension on post-heart transplant outcomes in bridge-to-transplant patients.

https://arctichealth.org/en/permalink/ahliterature96392
Source
J Heart Lung Transplant. 2010 Jul 8;
Publication Type
Article
Date
Jul-8-2010
Author
Ana Carolina Alba
Vivek Rao
Heather J Ross
Annette S Jensen
Kaare Sander
Finn Gustafsson
Diego H Delgado
Author Affiliation
Division of Cardiology and Heart Transplantation, University Health Network, Toronto, Ontario, Canada.
Source
J Heart Lung Transplant. 2010 Jul 8;
Date
Jul-8-2010
Language
English
Publication Type
Article
Abstract
BACKGROUND: Fixed pulmonary hypertension (FPH) is considered a contraindication to cardiac transplantation. Ventricular assist device (VAD) therapy through prolonged left ventricular unloading may reverse FPH. Our aim was to assess post-transplant outcomes and survival in patients with and without FPH undergoing VAD implantation as bridge to transplant. METHODS: Fifty-four patients received an intracorporeal left VAD (LVAD) as a bridge to transplant from 2000 to 2008 at two institutions (Rigshospitalet, Denmark, and the Toronto General Hospital, Canada). Twenty-two (41%) patients had fixed FPH (defined as pulmonary vascular resistance [PVR] >3 Wood units and resistant to pulmonary vasodilators) prior to VAD implant (FPH group) and were compared with 32 patients without FPH (NoFPH group). Baseline characteristics, pre- and post-transplant pulmonary pressures, incidence of complications and post-transplant survival were analyzed. RESULTS: Baseline characteristics were similar except that patients in the FPH group were older (46 +/- 11 years vs 39 +/- 13 years in the NoFPH group, p
PubMed ID
20620083 View in PubMed
Less detail